
Corcept Therapeutics Incorporated (CORT) Stock Overview
Explore Corcept Therapeutics Incorporated’s financial performance, market position, analyst ratings, and future outlook.
Corcept Therapeutics Incorporated (CORT)
Key Financials
Key Financials
Market Cap
12.3B
P/E Ratio
219.87
EPS (TTM)
$0.35
ROE
0.08%
CORT Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Corcept Therapeutics Incorporated (NASDAQ: CORT) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Corcept Therapeutics Incorporated's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of CORT on the NASDAQ shows an RSI of 67.01, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $72.97 for the NASDAQ listing.
Key metrics behind Corcept Therapeutics Incorporated's NASDAQ-traded stock include a P/E ratio of 219.87 and a market capitalization of 12.3B. Combined with our AI analysis, these give both institutional and retail investors a clear view of CORT on the NASDAQ.